Obesity is associated with lower testosterone in some men, and meaningful weight loss can improve levels. Diagnosis still requires compatible symptoms and properly collected repeat blood tests.
Obesity and lower testosterone frequently occur together, but the relationship is not a simple one-way cause. Increased adiposity, insulin resistance, sleep apnoea, illness and lower sex hormone-binding globulin can all influence testosterone results and symptoms. In men with obesity-related functional hypogonadism, meaningful weight loss can increase testosterone, but it does not guarantee that every symptom will resolve.
Testosterone should not be prescribed as a weight-loss treatment. A diagnosis of hypogonadism requires compatible clinical features and consistently low testosterone measured under appropriate conditions, followed by investigation of the cause.
Testosterone is produced primarily by the testes under signals from the hypothalamus and pituitary gland. This system is influenced by energy balance, sleep, illness, medicines and metabolic health.
In some men, obesity suppresses the signalling that supports testosterone production. Increased adipose tissue can also alter hormone metabolism and is commonly associated with insulin resistance, inflammation and obstructive sleep apnoea. The result may be functional secondary hypogonadism: the reproductive system is suppressed without permanent structural damage to the testes or pituitary.
The relationship can operate in both directions. Clinically significant testosterone deficiency may contribute to reduced muscle mass, lower activity, increased fat mass and poorer wellbeing. At the same time, obesity and its associated conditions can lower testosterone and produce similar symptoms.
An association does not identify which mechanism is responsible in one man. That requires a clinical history and correctly interpreted testing.
Testosterone circulates partly bound to sex hormone-binding globulin, known as SHBG. Obesity and insulin resistance often reduce SHBG. When SHBG is low, total testosterone can appear low even when androgen activity is less severely affected.
The Society for Endocrinology has highlighted this as an important source of overdiagnosis: some men with obesity have slightly low total testosterone because SHBG is low, while calculated free testosterone and the clinical picture provide additional context. Society for Endocrinology overview
A single total-testosterone result from a commercial panel should not be labelled "low T" without the collection conditions, laboratory method, SHBG and symptoms.
More specific features include:
Other symptoms are common but less specific:
These can arise from sleep apnoea, depression, diabetes, cardiovascular disease, thyroid problems, medication effects, excessive training, under-recovery, alcohol, nutritional restriction and many other causes. Good assessment keeps those alternatives open.
Current European guidance recommends measuring total testosterone in the morning, generally between 07:00 and 10:00, in the fasting state and with a reliable laboratory assay. A low result should be repeated on a separate occasion before treatment is considered. EAU male hypogonadism guideline
The joint Society for Endocrinology and Association for Laboratory Medicine position statement similarly advises testing men with compatible symptoms using morning fasting samples when they are not acutely ill. UK biochemical confirmation statement
The clinician may then consider:
Testing during acute illness, after inadequate sleep, following food intake or at inconsistent times can make interpretation more difficult. Shift workers may require timing based on their main sleep period rather than a conventional clock time.
Yes, particularly in men with obesity and suppressed testosterone, but the response varies.
A systematic review and meta-analysis of 24 studies found that weight loss through a low-calorie diet or bariatric surgery was associated with increased total testosterone, with larger increases in men who lost more weight. The evidence was heterogeneous and much of it predates current weight-management medicines, so it should not be converted into an individual promise. Corona et al. meta-analysis
The European Academy of Andrology recommends lifestyle change, physical exercise and weight reduction in overweight or obese men with functional hypogonadism because weight loss may increase testosterone. EAA functional hypogonadism guideline
In 2026, the Endocrine Society reiterated that reversible contributors such as obesity and relevant medicines should be addressed and that weight loss is typically first-line when hypogonadism is appropriately diagnosed as related to overweight or obesity and no other cause is identified. Endocrine Society statement
The important word is "may". Hormone values can improve without symptoms fully resolving, and persistent biochemical or clinical abnormalities need reassessment rather than an assumption that more weight loss is the only answer.
The evidence is strongest for the relationship between the amount of meaningful weight loss and testosterone change, not for a unique hormone effect from one branded diet or medicine.
Nutrition, physical activity, behavioural support, prescription weight-management medicine and bariatric surgery can all contribute to weight loss in appropriate patients. The chosen approach should be based on clinical suitability, likely benefit, risk and patient preference.
Claims that a specific GLP-1 medicine directly "boosts testosterone" go beyond the current evidence. If testosterone increases while a man loses weight on treatment, weight reduction and improved metabolic health may be important mediators. The medicine should still be prescribed for a licensed and clinically appropriate indication, not as hormone therapy.
No. Testosterone therapy is used for appropriately diagnosed hypogonadism after the cause, benefits, risks and alternatives have been assessed. It is not licensed as a general obesity treatment and should not be offered simply because a man wants to lose fat or gain muscle.
In men with genuine hypogonadism, treatment can alter body composition by increasing lean mass and reducing fat mass. That is not the same as proving safe, durable weight loss, and scale weight may not change in the way a patient expects.
The decision to prescribe testosterone should be driven by a valid diagnosis and clinical objectives, not a before-and-after promise. Monitoring is required, and treatment can have important risks and contraindications.
Fertility plans must be discussed before testosterone treatment. External testosterone suppresses luteinising hormone and follicle-stimulating hormone, which can markedly reduce sperm production and may cause infertility.
The Endocrine Society recommends against starting testosterone therapy in men planning fertility in the near term. Endocrine Society clinical guideline
A man with low testosterone symptoms who wants children needs an andrology or fertility-aware pathway. The priority is to establish whether the problem is primary or secondary, assess semen and reproductive history where appropriate, address reversible contributors and discuss treatments that are compatible with the fertility objective.
Never assume that testosterone treatment will improve fertility because it increases a blood hormone level. The opposite can happen to sperm production.
Weight loss usually includes some loss of fat-free tissue as well as fat. Men concerned about testosterone often focus on preserving strength and muscle, but hormone treatment is not the default solution.
The foundation is:
If confirmed hypogonadism is present, its management should be integrated with this plan. If it is not, non-prescribed testosterone or anabolic steroids create additional endocrine, cardiovascular and fertility risks without correcting the actual cause of symptoms.
Consider clinical assessment when compatible symptoms are persistent, particularly sexual symptoms, infertility, loss of muscle or strength, reduced testicular size, hot flushes, unexplained anaemia or low bone density.
Assessment is also appropriate when:
Urgent symptoms require the appropriate urgent pathway rather than an online hormone discussion.
A safe integrated pathway should:
This is the Heracles advantage: weight and testosterone are assessed as connected clinical questions without treating either as a shortcut to the other.
External testosterone can suppress sperm production. Men who want to conceive should discuss this before any treatment and use a fertility-aware specialist pathway.
It may be reasonable when an earlier result was low or symptoms persist. Timing should be agreed with the clinician and testing should use appropriate fasting morning conditions.
